Evotec (ETR:EVT) has been given a €23.00 ($26.74) target price by analysts at Deutsche Bank in a research note issued on Friday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. Deutsche Bank’s price objective points to a potential downside of 1.71% from the company’s previous close.
Separately, Berenberg Bank set a €20.00 ($23.26) target price on shares of Evotec and gave the stock a “neutral” rating in a report on Tuesday, March 5th.
EVT opened at €23.40 ($27.21) on Friday. The firm has a market capitalization of $3.48 billion and a PE ratio of 41.79. The company has a debt-to-equity ratio of 26.94, a current ratio of 1.27 and a quick ratio of 1.18. Evotec has a 12 month low of €12.18 ($14.16) and a 12 month high of €25.83 ($30.03).
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Featured Article: What is the Coverage Ratio?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.